Navigation Links
Abbott Hosts Conference Call for Fourth-Quarter and Full-Year 2007 Earnings
Date:1/3/2008

ABBOTT PARK, Ill., Jan. 3 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) will announce its financial results for the fourth-quarter and full year ended Dec. 31, 2007, on Wednesday, Jan. 23, 2008, before the market opens.

The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern), and will be accessible through Abbott's Investor Relations Web site at http://www.abbottinvestor.com. An archived edition of the call will be available after 11 a.m. Central time.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Abbott to Present at Bear Stearns Healthcare Conference
2. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
3. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
4. Abbott Declares 335th Consecutive Quarterly Dividend
5. Abbott Again Honored as Top Company for Working Moms
6. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
7. Abbott Hosts Conference Call for Third-Quarter Earnings
8. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
9. Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine
10. Abbott Again Honored as a Leader in Diversity
11. Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...ar herpes simplex virus is a common eye disease af...have the disease, and about 50,000 new cases are i...e HSV-type 1 virus. Most people who get the infe...currence rate is about 20 percent within two years...
...xic Respiratory Failure ( HRF ) develops when newb...body. //It can happen to full-term and near-term i...to predict which infants will develop HRF, so ther.... The standard treatment is a surgical procedure t...
...archers from the University of Florida College of ...two different treatments for hypertension in older... more than one medication to control their blood p...at multidrug strategies rather than individual dru...
...ntists believe they’ve found a simple new test to ...ble stage.// In a report published in this week’s...ed on an analysis of a person’s urine. Kidney canc...percent of all cancers. About 32,000 cases were id...
Other Medicine News:
(Date:9/5/2008)...SAN FRANCISCO, Calif., Sept. 5 /PRNewswire-FirstCa...sed on small molecule LFA-1 inhibitors,to treat in...Inc. (Nasdaq:,SNSS) today announced SARcode,s init...cule LFA-1 product candidate for T-cell mediated o...to a license agreement providing,SARcode with an e...
(Date:9/4/2008)... awarded orphan designation for the treatment of A...ia, PRINCETON, N.J., Sept. 4 /- Cela...Food & Drug Administration (FDA) has granted orpha...icin) Liposome Injection,for the treatment of Acut...reparing to conduct two randomized Phase 2,studies...
(Date:9/4/2008)...ce Bulletin for Obstetrician-Gynecologists States ...hange-Minimally Invasive Interventional,Radiology ... Uterine,Fibroids, FAIRFAX, Va., Sept. 4 /PRNewsw...adiology, a national organization of nearly 4,500 ...s dedicated to improving health,care through minim...
(Date:9/4/2008)... Updated Survival Data for Ipilimumab to be Prese...all/ -- Medarex, Inc.,(Nasdaq: MEDX ) announced t...an investigational anti-CTLA-4 antibody, in melano...s at the 33rd Congress of the European Society,for...6, 2008 in Stockholm.,Many of the following abstra...
Breaking Medicine Technology:SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 2SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 3Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351 2Society of Interventional Radiology Applauds Report's Uterine Fibroid Embolization Recommendations 2Society of Interventional Radiology Applauds Report's Uterine Fibroid Embolization Recommendations 3Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 2Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 3AcroMetrix Releases New OptiQuant 28R 29 HIV 1 Quantification Panel 598 1AcroMetrix Releases New OptiQuant 28R 29 HIV 1 Quantification Panel 598 2Dynavax Begins TOLAMBA 28TM 29 Environmental Exposure Chamber Study 596 1Dynavax Begins TOLAMBA 28TM 29 Environmental Exposure Chamber Study 596 2Dynavax Begins TOLAMBA 28TM 29 Environmental Exposure Chamber Study 596 3Weight gain related to postmenopausal breast cancer risk 4302 1Weight gain related to postmenopausal breast cancer risk 4302 2Whole Grains Do a Heart Good 4300 1Whole Grains Do a Heart Good 4300 2Whole Grains Do a Heart Good 4300 3
...ons Unite to Help Educate on Good,Diabetes Managem...alth Problems, SEATTLE, April 10, 2007 /PRNewswire...valence and cost of type 2 diabetes,complications ...57.9 percent) with type 2 diabetes have at least o...ssociated with the disease, and,that these health ...
...ewswire-FirstCall/ -- ImClone,Systems Incorporated...that a Phase III study of ERBITUX(R) (Cetuximab) p...locally advanced,unresectable or metastatic pancre...mproving overall survival. , Conducted by the Sout...rk sponsored by the National Cancer Institute, the...
Other Medicine Technology:First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 2First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 3First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 4First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 5First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 6First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 7Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 2Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 3Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 4Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 5Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 6Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 7Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 8Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 9
Hand Drill, with two-position Handle, with Jacob three-jaw chuck, wrench-locked for changing twist drills up to 6 mm
Hudson brace only. Component parts and accessories for Hudson cranial drill.
Width 3 (76 mm), length 6 3/4 (171 mm). Pattie Tray attaches to long or short arm.
Kit is supplied with four secondary bars. Secondary bars attach to primary bar. Length 12 (305 mm).
Medicine Products: